Roche said the layoffs at its Madison, Wisconsin site will start Dec. 31 and continue through June 30, 2020.
The company is developing tests based on the analysis of the spatial patterns of chromosomes by tagging and imaging their telomeres.
The company said the layoffs are part of a cost-reduction plan that aims to initially cut annual operating expenses by $1.7 million.
The restructuring and job cuts are expected to save the firm more than $70 million annually.
The decisions are part of the company's restructuring efforts after it was unable to extend deferral of its debt payment with its senior lender.
The moves are part of an effort to consolidate and reduce costs related to administrative, finance, and operational support functions.
The firm said that it planned to lay off its oncology sales team in order to focus on women's health, despite launching an oncology business unit last spring.
In October, Roche reported the tissue diagnostics business contributed 8 percent to diagnostics sales in the first nine months of 2016.
The firm's CEO Ramji Srinivasan said the layoffs would help focus the company on developing relationships with clinicians and medical providers.
In November, the company said it was selling off its biomedical commercialization and marketing services business in order to focus on its diagnostic offerings.
An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.
The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.
In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.
Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.